跳至主要内容
临床试验/RBR-86kcy37
RBR-86kcy37尚未招募3 期

Evaluation of the efficacy and safety of pediatric praziquantel in children residing in endemic areas of Bahia and Sergipe

Instituto Gonçalo Moniz (IGM) - Fundação Oswaldo Cruz (Fiocruz-BA)0 个研究点开始时间: 2024年6月14日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
3M 至 6Y(—)

入选标准

  • Age between 4 and 6 years (cohort 1) and 3 months to 3 years (cohort 2); presence of at least 1 Schistosoma mansoni egg detected through parasitological methods; minimum body weight of 8 kg for children between 2 and 6 years and 5 kg for children under 2 years

排除标准

  • Presence of conditions that contraindicate the use of praziquantel at the discretion of the physician, such as viral or bacterial infections, diarrhea, gastroenteritis, among others; have undergone treatment with praziquantel in the last 6 months; concomitant treatment with other drugs that can affect the metabolism of praziquantel, such as some antiepileptics, glucocorticoids, chloroquine, rifampicin, or cimetidine; participants with hepatosplenic schistosomiasis; participants with body temperature above 37.5°C

研究者

发起方
Instituto Gonçalo Moniz (IGM) - Fundação Oswaldo Cruz (Fiocruz-BA)

相似试验

Assessment of praziquantel medication for children... | 临床试验